Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Avon Foundation Breast Cancer Prevention Research Initiative has awarded A&G Pharmaceutical an $870,000 grant to conduct multicenter clinical studies focused on measuring levels of A&G's proprietary breast cancer biomarker, GP88, in blood and tissue samples from breast cancer patients.
Subscribe to our email newsletter
Results of the studies could provide the basis for developing a blood test that would enable early detection of breast cancer.
According to A&G, the award was one of 12 grants totaling more than $7 million awarded in 2007 by the Avon Foundation as part of its Breast Cancer Prevention Research Initiative, and it is the first ever awarded by the foundation to a private company.
Ginette Serrero, CEO of A&G, said: “We greatly appreciate Avon’s support as we accelerate the development of a GP88 blood diagnostic test and our goal of establishing GP88 as the most sensitive and reliable marker for early breast cancer detection.”